Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel Agents

Inhibitors of B-cell receptor signaling, ibrutinib and idelalisib, and BCL-2 antagonist, venetoclax, have become the mainstay of treatment for chronic lymphocytic leukemia (CLL). Despite significant efficacy in most CLL patients, some patients develop resistance to these agents and progress on these...

Full description

Saved in:
Bibliographic Details
Published in:Front Oncol
Main Authors: Sedlarikova, Lenka, Petrackova, Anna, Papajik, Tomas, Turcsanyi, Peter, Kriegova, Eva
Format: Artigo
Language:Inglês
Published: Frontiers Media S.A. 2020
Subjects:
Oncology
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7330112/
https://ncbi.nlm.nih.gov/pubmed/32670873
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00894
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items